Literature DB >> 3170109

High-dose ketoconazole treatment in advanced prostatic cancer.

S Scultéty1, J Oszlánczy, I Faredin, I Tóth.   

Abstract

For purposes of testosterone suppression, high doses of ketoconazole were administered to 18 patients with advanced cancer of the prostate for an average of 6 months. A well-evaluable response was observed both objectively and subjectively. The blood levels of the steroid hormones were measured during the treatment period and it was found that testosterone biosynthesis was blocked. Mild gastrointestinal symptoms occurred in the minority of the cases, and administration of the drug had to be stopped in one case because of jaundice. The possibility of the use of smaller doses is being investigated, which may lead to the development of an alternative to the endocrine treatment methods.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170109     DOI: 10.1007/bf02549571

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  7 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Ketoconazole therapy in advanced prostatic cancer.

Authors:  J Trachtenberg
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450

3.  Ketoconazole blocks testosterone synthesis.

Authors:  A Pont; P L Williams; S Azhar; R E Reitz; C Bochra; E R Smith; D A Stevens
Journal:  Arch Intern Med       Date:  1982-11

4.  New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.

Authors:  F Labrie; A Dupont; A Belanger; Y Lacoursiere; J P Raynaud; J M Husson; J Gareau; A T Fazekas; J Sandow; G Monfette
Journal:  Prostate       Date:  1983       Impact factor: 4.104

5.  Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer.

Authors:  G Williams; D J Kerle; H Ware; A Doble; H Dunlop; C Smith; J Allen; T Yeo; S R Bloom
Journal:  Br J Urol       Date:  1986-02

6.  Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.

Authors:  D S Loose; P B Kan; M A Hirst; R A Marcus; D Feldman
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

7.  Site of action of low dose ketoconazole on androgen biosynthesis in men.

Authors:  R J Santen; H Van den Bossche; J Symoens; J Brugmans; R DeCoster
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

  7 in total
  1 in total

1.  In vitro inhibition of testicular delta 5-3 beta-hydroxysteroid dehydrogenase and prostatic 5 alpha-reductase activities in rats and humans by strogen forte extract.

Authors:  I Tóth; M Szécsi; J Julesz; I Faredin; B Behnke
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.